Brands & Strategies: UA/NSTEMI

Abstract

Introduction

In 2006, the unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI) market, valued at more than $820 million in the United States, Europe, and Japan, was dominated by a handful of premium-priced therapies, including Schering-Plough' s gpIIb/IIIa inhibitor Integrilin and Sanofi-Aventis' low-molecular weight heparin Lovenox. Nine existing drug classes and complicated treatment regimens make for a crowded and competitive market; nonetheless, huge unmet clinical need provides an attractive commercial opportunity for new treatments that demonstrate efficacy and safety superior to that of currently available treatments. Several new agents are set to enter the market before 2011, including Eli Lilly' s ADP receptor antagonist prasugrel, GlaxoSmithKline' s Factor Xa inhibitor Arixtra, Schering-Plough' s thrombin receptor antagonist SCH-530348, and The Medicines Company' s cangrelor. The launch of these drugs will impact currently available therapies and contribute to revenue growth, driving the UA/NSTEMI market to more than $1 billion in 2011.

Questions Answered in This Report

• Schering-Plough dominated the UA/NSTEMI market in 2006, with a market share in excess of 40%, almost double that of the next leading competitor. How has Schering-Plough secured such a dominant market share? What strategies will the company employ to sustain a leading position over the forecast period?
• Cardiologists and interventional cardiologists have been cautious in their uptake of expensive new agents because of the need for cost containment and the lack of perceived improvement over existing agents. What do physicians identify as the key attributes of currently marketed agents? What are the perceived advantages and/or disadvantages of emerging therapies versus available therapies?
• Plavix is currently the gold standard for antiplatelet therapy; however, Eli Lilly' s highly anticipated prasugrel and The Medicines Company' s cangrelor have the potential to radically change the ADP receptor antagonist drug class dynamic. Other agents in development also have the potential to compete directly with Plavix. What products are being developed in the major competitors' pipelines? How will emerging drugs perform if approved for UA/NSTEMI treatment?
• UA/NSTEMI is part of a broader set of cardiovascular conditions that includes acute coronary syndrome (ACS) and thrombosis-related disorders, and it is distinct from primary care cardiovascular conditions such as dyslipidemia and hypertension. How does UA/NSTEMI fit into the wider cardiovascular therapeutic area? What strategies are being pursued to achieve success in this treatment area?

Scope

• Markets Covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
• Competitive Analysis: Detailed discussion of major competitors, including Schering-Plough, Sanofi-Aventis, Bristol-Myers Squibb, Eli Lilly, Merck, and The Medicines Company, as well as the emerging competitor GlaxoSmithKline. Included is an analysis of each company' s cardiovascular product portfolio, strategic positioning, and development pipeline in UA/NSTEMI. The report features an in-depth discussion of leading brands including approval history, sales and market position, SWOT analysis, and strategy initiatives.
• Physician Perception of Key Brands: Analysis of physician perceptions of the UA/NSTEMI market based on a custom survey of 50 U.S. cardiologists and interventional cardiologists. The survey is brand-focused and examines physician perceptions of key competitors, brand attributes, and uptake of emerging agents.
• Epidemiology: Total prevalent and diagnosed cases for each of the major markets are presented in an annualized forecast from 2006 to 2011.
• Market Forecast: Annualized sales forecasts for branded agents presented by region, drug class, molecule, and brand for 2006 to 2011, including the uptake of new agents.